

## **VENTAVIS® (iloprost)** **Concomitant Use of VENTAVIS With COVID-19 Vaccines**

### **SUMMARY**

- **Use With COVID-19 Vaccines**

- Currently, there are no published studies on the concomitant use of other manufacturers' COVID-19 vaccines and VENTAVIS.
- Clinicians should use clinical judgement based on local/institutional guidelines, standards of care, and individual patient risk/benefit assessment when considering concomitant use of VENTAVIS and COVID-19 vaccines.
- For additional information regarding the use of COVID-19 vaccines, please refer to the vaccine manufacturer.

- **General Vaccination Information**

- Please refer to your local labeling for information on VENTAVIS and use of vaccines.
- Refer to the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices COVID-19 Vaccine Recommendations.<sup>1</sup>
- Country-specific health authority and medical society recommendations may be available regarding the use of COVID-19 vaccines in patients with pulmonary arterial hypertension. Relevant content from the most recognized organizations are listed below. However, this list is not a complete list of publicly available resources. The content is subject to change as evidence evolves.
  - For information from the World Health Organization (WHO), visit: [COVID-19 vaccines](#).
  - For information from the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices, visit: [COVID-19 ACIP Vaccine Recommendations](#).
  - European Society of Cardiology (ESC): [COVID-19 and Cardiology](#).
  - American Lung Association (ALA): [Preventing COVID-19](#).

### **LITERATURE SEARCH**

A literature search of MEDLINE®, EMBASE, BIOSIS Previews®, Derwent® (and/or other resources, including internal/external databases) was conducted on 10 January 2024.

### **REFERENCES**

1. Centers for Disease Control and Prevention (CDC). COVID-19 ACIP vaccine recommendations. Centers for Disease Control and Prevention (CDC); 2020. Accessed January 16, 2024.